⁃ In order to be eligible to participate in this study, subjects must meet all of the following criteria:

• Requires primary hip resurfacing arthroplasty due to:

∙ non-inflammatory arthritis (degenerative joint disease) such as osteoarthritis, traumatic arthritis, or

‣ mild dysplasia/developmental dislocation of the hip (DDH) up to Crowe Grade 1.

• Harris Hip Score \< 70 points.

• Skeletally mature, age ≥21 and \<65 years.

• Physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms and willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol.

⁃ Subjects who meet any of the following criteria will be excluded from participating in this study:

• Inadequate bone stock or bone quality to support the device based on a Canal-Bone Ratio (CBR-7) of \>0.45.0F

• Severe osteopenia, a medical history or increased risk of severe osteoporosis or severe osteopenia, a history of fragility fracture, and other conditions that lead to increased bone resorption

• Osteonecrosis or avascular necrosis (AVN)

• Multiple cysts of the femoral head (\> 1cm) or cysts crossing the head-neck junction

• Metabolic disorders which may impair bone formation (e.g., osteomalacia, osteogenesis imperfecta, parathyroid disease, rickets, etc.)

• Severe femoral head deformities that will prevent fixation of the prosthetic resurfacing femoral head

• Inflammatory arthritis such as rheumatoid arthritis (RA)

• Severe proximal femoral rotational deformity in whom appropriate combined anteversion of femoral-acetabular construct is unachievable

• Severe acetabular dysplasia/development dislocation of the hip, defined as Crowe Grade ≥ 2

⁃ Previous surgical intervention on index hip (e.g., treatment of hip fracture, arthroscopy)

⁃ Severe medical comorbidities, including:

• severe cardiopulmonary disease,

∙ congestive heart failure,

∙ severe liver or kidney dysfunction,

∙ end-stage renal disease,

∙ severe uncontrolled diabetes,

∙ history of IV drug use,

∙ history of hypercoagulable state or pulmonary embolism,

∙ severe lumbar spinal stenosis,

∙ vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or post-operative recovery,

• neuropathic arthropathy (Charcot joint),

• immunosuppression or other immunodeficiency disorders, e.g., diseases such as Acquired Immune Deficiency Syndrome (AIDS) or post-organ transplant and on high doses of corticosteroids.

⁃ Incompetent or deficient soft tissue surrounding the joint (e.g., hip abductor muscle deficiency)

⁃ BMI \> 40

⁃ Active or suspected infection in or around the hip joint

⁃ Known or suspected metal sensitivity (e.g., jewelry) or allergy to any implant materials

⁃ Pregnant or plan to become pregnant during the study duration

⁃ Current smoker